Effect of Megestrol Acetate in patients with cancer associated cachexia.

Evaluation of Megestrol Acetate in treating Cancer related Cachexia: A Single Arm Pilot Study - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/096927

Enrollment

Registered

2025-11-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C801- Malignant (primary) neoplasm, unspecified

Interventions

Intervention1: Megestrol Acetate: Megestrol Acetate, 480mg daily in three divided dose orally for 6 weeks Control Intervention1: N/A: N/A

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are clinically diagnosed with cancer associated Cachexia and histologically confirmed Cancer. Patients who can provide voluntary informed consent and can take oral medication are included.

Exclusion criteria

Exclusion criteria: Patients with history of Thromboembolic disease, severe Renal or Hepatic impairment. Patient who received corticosteroids or appetite stimulant in past 2 weeks are excluded.

Design outcomes

Primary

Measure	Time frame
To determine the impact of Megestrol Acetate on body composition in cachectic patients with a specific focus on changes in lean body mass, fat mass, and bone mineral content as quantified by DEXA scan and Sr.albumin levelTimepoint: DEXA Scan - Week 0 & Week 6 Sr.Albumin- Week 0 & Week 6	—

Secondary

Measure	Time frame
to assess improvement in appetite and food intake by using FAACT appetite scaleTimepoint: FAACT appetite scale - week0 & week6	—

Countries

India

Contacts

Public ContactSwetha S

SRM Institute of Science and Technology, Kattankulathur.

vijayakm2@srmist.edu.in9003400350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026